Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ernesto J Muñoz-Elías"'
Autor:
Eric J Tarcha, Chelsea M Olsen, Peter Probst, David Peckham, Ernesto J Muñoz-Elías, James G Kruger, Shawn P Iadonato
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0180762 (2017)
Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which have been shown to be key mediators of autoimmune diseases,
Externí odkaz:
https://doaj.org/article/f137890bf7c24d3ebf96fb3d4a62b3ef
Autor:
Andrew Blauvelt, Yanqing Chen, Patrick J. Branigan, Xuejun Liu, Samuel DePrimo, Brice E. Keyes, Monica Leung, Steven Fakharzadeh, Ya-Wen Yang, Ernesto J. Muñoz-Elías, James G. Krueger, Richard G. Langley
Publikováno v:
JID Innovations, Vol 4, Iss 5, Pp 100297- (2024)
IL-23 is a cytokine produced by myeloid cells that drives the T helper 17 pathway and plays an essential role in the pathophysiology of plaque psoriasis. IL-23 activation initiates a cascade of cytokines subsequently inducing the expression of many p
Externí odkaz:
https://doaj.org/article/3cdb3a1625bb4d1bb4480d62cb6cb130
Autor:
Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp
Publikováno v:
JID Innovations, Vol 4, Iss 5, Pp 100287- (2024)
Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses. Selective blockade of IL-23p19 with guselkum
Externí odkaz:
https://doaj.org/article/b95df6bc33d542458a2fcbb40566670b
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/e7269705260f446ea8a65c4e712f0fd1
Autor:
Lucas L Lintermans, Coen A Stegeman, Ernesto J Muñoz-Elías, Eric J Tarcha, Shawn P Iadonato, Abraham Rutgers, Peter Heeringa, Wayel H Abdulahad
Publikováno v:
Rheumatology.
Objectives Granulomatosis with polyangiitis (GPA) is a chronic relapsing systemic autoimmune vasculitis. Current treatment of GPA is unsatisfactory, as it relies on strong immunosuppressive regimens, with either CYC or rituximab, which reduce the imm
The biological basis of disease recurrence in psoriasis: a historical perspective and current models
Autor:
Lluís Puig, Antonio Costanzo, Ernesto J. Muñoz‐Elías, Maria Jazra, Sven Wegner, Carle F. Paul, Curdin Conrad
Publikováno v:
British Journal of Dermatology. 186:773-781
A key challenge in psoriasis therapy is the tendency for lesions to recur in previously affected anatomical locations after treatment discontinuation following lesion resolution. Available evidence supports the concept of a localized immunological 'm
Autor:
Weiyang Tao, Juliëtte N Pouw, Julia Drylewicz, Samuel E. DePrimo, Ernesto J. Muñoz-Elías, Marianne Boes, Tessa S. van Kempen, Deepak M.W. Balak, Timothy R D J Radstake, Aridaman Pandit, Emmerik F A Leijten, Janneke Tekstra, Michel Olde Nordkamp
Publikováno v:
Rheumatology (Oxford, England)
Objective To identify novel serum proteins involved in the pathogenesis of PsA as compared with healthy controls, psoriasis (Pso) and AS, and to explore which proteins best correlated to major clinical features of the disease. Methods A high-throughp
Publikováno v:
EMJ Dermatology. :10-16
Guselkumab was the first monoclonal antibody targeting the p19 subunit of IL-23 (IL-23p19) to be approved for the treatment of psoriasis. The registrational trials VOYAGE 1 and 2 established the efficacy and safety profile of guselkumab to Week 48 an
Autor:
Khusru Asadullah, Andreas Pinter, Kilian Eyerich, Friedmann J H Taut, Holger Bartz, Ernesto J. Muñoz-Elías, Sven Wegner, Knut Schäkel, Peter Weisenseel, Kristian Reich
Publikováno v:
BMJ Open, Vol 11, Iss 9 (2021)
BackgroundGuselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later interventio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e0ee3a8ed6c7a530b558e9f07a8901c
http://publikationen.ub.uni-frankfurt.de/files/63018/e049822_full.pdf
http://publikationen.ub.uni-frankfurt.de/files/63018/e049822_full.pdf
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)